Contrasting Summit Therapeutics (NASDAQ:SMMT) & GelStat (OTCMKTS:GSAC)

GelStat (OTCMKTS:GSAC) and Summit Therapeutics (NASDAQ:SMMT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.

Risk and Volatility

GelStat has a beta of 2.86, indicating that its stock price is 186% more volatile than the S&P 500. Comparatively, Summit Therapeutics has a beta of -1.21, indicating that its stock price is 221% less volatile than the S&P 500.

Insider and Institutional Ownership

4.6% of Summit Therapeutics shares are owned by institutional investors. 20.5% of GelStat shares are owned by company insiders. Comparatively, 84.9% of Summit Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares GelStat and Summit Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GelStat	N/A	N/A	N/A	N/A	N/A
Summit Therapeutics	N/A	N/A	-$221.32 million	($1.24)	-13.92

Analyst Ratings

This is a summary of current recommendations for GelStat and Summit Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GelStat	0	0	0	0	0.00
Summit Therapeutics	4	3	11	1	2.47

Summit Therapeutics has a consensus target price of $31.14, suggesting a potential upside of 80.43%. Given Summit Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Summit Therapeutics is more favorable than GelStat.

Profitability

This table compares GelStat and Summit Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
GelStat	N/A	N/A	N/A
Summit Therapeutics	N/A	-311.15%	-262.35%

Summary

Summit Therapeutics beats GelStat on 6 of the 9 factors compared between the two stocks.

About GelStat

GelStat Corporation, a consumer health care company, engages in the research, development, and marketing of over-the-counter and other non-prescription consumer health care products. Its products include GelStat Migraine, a patented solution used for pain relief from migraine headaches; Chews 2 Lose, an appetite suppressant gum for diet aide; All Natural Speed, an energy supplement product; and GelStat Sleep, a product for relief from sleep disorders and its associated symptoms. The company sells its products to retailers, wholesalers, specialty distributors, and catalog merchandisers both directly and through external sales brokers. GelStat Corporation was founded in 2002 and is headquartered in Palm City, Florida.

About Summit Therapeutics

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company’s lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.